APA (7th ed.) Citation

Dahiya, S., Ulrickson, M. L., Topp, M. S., Kersten, M. J., Yared, J., Reagan, P. M., . . . Nastoupil, L. (2025). 103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA. Hematological oncology, 43, 1. https://doi.org/10.1002/hon.70093_103

Chicago Style (17th ed.) Citation

Dahiya, S., et al. "103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA." Hematological Oncology 43 (2025): 1. https://doi.org/10.1002/hon.70093_103.

MLA (9th ed.) Citation

Dahiya, S., et al. "103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA." Hematological Oncology, vol. 43, 2025, p. 1, https://doi.org/10.1002/hon.70093_103.